Journal of Advances in Medical and Pharmaceutical Sciences https://journaljamps.com/index.php/JAMPS <p style="text-align: justify;"><strong>Journal of Advances in Medical and Pharmaceutical Sciences (ISSN: <a href="https://nsl.niscpr.res.in/ISSNPROCESS/issnassignedinfo.jsp">2394-1111</a>)</strong> aims to publish high quality papers (<a href="https://journaljamps.com/index.php/JAMPS/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of Medical and Pharmaceutical Sciences. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p> SCIENCEDOMAIN international en-US Journal of Advances in Medical and Pharmaceutical Sciences 2394-1111 Behavioural Responses to Limonene Pretreatment and Morphine in Mice: Hot-Plate, Open-Field, Rotarod, and Forced-Swim Assessments https://journaljamps.com/index.php/JAMPS/article/view/904 <p>Morphine affects nociceptive responses and motor behaviour in rodents, complicating interpretation of drug interactions. Limonene, a citrus-derived monoterpene, has been reported to exhibit biological activities, but its effects when administered before morphine remain uncertain. Thermal response latency, open-field locomotion, rotarod performance and forced-swim immobility were compared across eight groups of Swiss albino mice receiving saline, limonene, morphine (1, 3 or 5 mg/kg), or limonene before the corresponding morphine dose. The 48 mice (24 females and 24 males; six per group) underwent four assays separated by 15-day intervals. At later nominal hot-plate observation times, several morphine-only groups showed longer latencies than their corresponding combination groups. Morphine-only groups displayed higher open-field square-crossing counts than vehicle at 30–120 min, whereas combination groups generally showed lower counts than morphine alone. Rotarod residence time and forced-swim immobility differed across treatments without a uniform dose-dependent pattern. Findings are descriptive because individual-animal observations, defined statistical contrasts and complete test outputs are not reported. Unresolved dose, timing and recording discrepancies prevent conclusions regarding analgesic enhancement, motor protection, opioid sparing or antidepressant efficacy.</p> Kona Basak Rebecca Cynthia Gomes Maria Chowdhury Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-10-26 2026-10-26 28 11 20 28 10.9734/jamps/2026/v28i11904 Association of Neutrophil-to-Lymphocyte Ratio with Etiology and Severity of Acute Exacerbation of COPD https://journaljamps.com/index.php/JAMPS/article/view/906 <p><strong>Background:</strong> Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) refer to an abrupt deterioration in airway function and respiratory symptoms among individuals with COPD. The neutrophil-to-lymphocyte ratio (NLR) is a simple, cost-effective biomarker of systemic inflammation. Early diagnosis and clinical assessment may be enhanced by assessing the relationship between NLR and the aetiology and severity of AECOPD.</p> <p><strong>Objective:</strong> To assess the association of the neutrophil-to-lymphocyte ratio (NLR) with the aetiology and severity of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).</p> <p><strong>Methods:</strong> This cross-sectional observational study enrolled 180 patients with AECOPD through convenience sampling at the Department of Medicine, North East Medical College Hospital, Sylhet, over an eight-month period. Clinical information was recorded, and venous blood samples were collected for complete blood count, differential leucocyte count and C-reactive protein assessment. Patients were classified as having infectious exacerbations based on the study's specified inflammatory laboratory criteria. Associations were evaluated using the Mann–Whitney U test, receiver operating characteristic analysis and univariate logistic regression.</p> <p><strong>Results:</strong> Of 180 patients, 126 (70%) were classified as having infectious exacerbations and 54 (30%) as having non-infectious exacerbations. The overall mean NLR was 6.78 ± 4.52. Mean NLR was higher in the infectious than the non-infectious group (5.96 versus 4.59; p = 0.014). An NLR cut-off of 5.12 distinguished severe or very severe exacerbations with 70.7% sensitivity, 73.0% specificity and an area under the curve of 0.772. NLR was associated with exacerbation severity in univariate regression (OR 1.347; 95% CI 1.171–1.550).&nbsp;</p> <p><strong>Conclusion:</strong> NLR was associated with presumed infectious aetiology and exacerbation severity in this hospital-based cohort and may have value as an adjunct to clinical assessment.</p> Mia Parvej S. N. Chowdhury A. K. Chowdhury M. S. R. Rumel A. Sayeed I. A. Z. Chowdhury F. Jannat D. Chowdhury R. Jannath Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-05 2026-11-05 28 11 39 46 10.9734/jamps/2026/v28i11906 Hepatoprotective, Nephroprotective, and Gastric Mucosal Defence Profiles of Viscum album Bioactive Extracts against Lead Toxicity https://journaljamps.com/index.php/JAMPS/article/view/907 <p>Lead acetate exposure can produce biochemical and histological disturbances in several organs. This study evaluated the protective effects of <em>Viscum album</em> leaf extract against lead acetate-induced toxicity in male Wistar albino rats. Thirty rats were randomly assigned to six groups of five animals each. Group 1 served as the normal control and received standard grower mash and water, while Groups 2–6 were administered lead acetate (10 mg/kg body weight) daily to induce toxicity. In addition to lead acetate exposure, Groups 2, 3, and 4 received <em>V. album</em> leaf extract at doses of 200, 400, and 800 mg/kg body weight, respectively. Group 5 served as the untreated lead-exposed control, whereas Group 6 served as the positive control and received omeprazole (500 mg/kg body weight). All treatments were administered for 28 days. Biochemical and haematological analyses indicated that treatment with <em>V. album</em> significantly (P &lt; 0.05) was associated with changes in body and organ weights and modulated liver enzyme activities and haematological indices compared with untreated lead-exposed rats. The extract also helped maintain renal function and electrolyte homeostasis, as assessed using serum urea, creatinine and electrolyte concentrations. Histopathological examination further demonstrated that <em>V. album</em> leaf extract ameliorated lead-induced tissue alterations in the gastric mucosa, liver, heart, and kidneys, with preservation of hepatocytes, cardiomyocytes, and renal architecture. These findings suggest that <em>V. album</em> leaf extract may exert protective effects against lead acetate-induced systemic toxicity in rats, potentially through the preservation of haematological, hepatic, renal, and tissue integrity. Further studies are warranted to elucidate the underlying mechanisms and identify the bioactive constituents responsible for these protective effects.</p> <p><strong>&nbsp;</strong></p> Silvanus Olu Innih Sylvia Oghogho Omage Ajayi Damilola Josiah Peter Benson Onyeije Deborah Calmday-Ombo Damilola Adelokhai Igbode Adedoja Egbon Precious Ogbebor Mercy Esther Akpojobaro Kingsley Omage Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-06 2026-11-06 28 11 47 62 10.9734/jamps/2026/v28i11907 Molecular Modelling and QSAR-Guided Design of Aminoquinoline-Pyrimidine Analogues Targeting Mutant Plasmodium falciparum DHFR-TS https://journaljamps.com/index.php/JAMPS/article/view/911 <p>Malaria remains a major public health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. The bifunctional dihydrofolate reductase-thymidylate synthase of <em>Plasmodium falciparum</em> (PfDHFR-TS) is an established antifolate target whose resistance-associated variants motivate ligand-directed discovery. This study combined molecular mechanics, Poisson-Boltzmann-based energy calculations, quantitative structure-activity relationship (QSAR) modelling, pharmacophore screening, in silico ADME prediction, and molecular dynamics to prioritise aminoquinoline-pyrimidine (AQPy) analogues. Twenty-three published AQPy compounds with whole-parasite antiplasmodial IC<sub>50</sub> values were divided into a training set of 19 compounds and an external validation set of four compounds. Docking was based on the quadruple-mutant PfDHFR-TS structure (PDB 1J3K). The free-energy descriptor model showed a training-set coefficient of determination of approximately 0.96 and a four-compound external pIC<sub>50</sub> root-mean-square error of approximately 0.23. A pharmacophore-guided design space produced 37 screened records corresponding to 33 distinct displayed compound identifiers. The most favourable modelled complexation-energy descriptors were associated with 15-106, 15-104, and 24-1. Calculated ADME descriptors and 200 ns molecular dynamics trajectories provided complementary information about the proposed binding poses and dynamic behaviour. Together, these results identify structural candidates for biochemical target testing and parasite-growth assays, while distinguishing the molecular-model rankings from experimentally measured inhibitory activity.</p> Konaté Souleymane Soro Issouf Kouakou Kouakou Jean-Louis Fofana Issouf Niaré Adama Kré N’Guessan Raymond Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-16 2026-11-16 28 11 100 123 10.9734/jamps/2026/v28i11911 Phytochemical Analysis, Antioxidant Activity, and Cardiovascular Effects of a Traditional Remedy Used in the Management of Hypertension https://journaljamps.com/index.php/JAMPS/article/view/913 <p><strong>Background: </strong>The traditional herbal formulation R2, prepared from the leaves of <em>Combretum micranthum</em>, <em>Phyllanthus amarus</em> and <em>Catharanthus roseus</em>, is used in the management of hypertension in Côte d’Ivoire. Its phytochemical composition, antioxidant activity and cardiovascular effects require formulation-specific evaluation.</p> <p><strong>Aims:</strong> This study aimed to investigate the phytochemical composition, antioxidant activity, and cardiovascular effects of the traditional herbal formulation R2, comprising <em>Combretum micranthum</em>, <em>Phyllanthus amarus</em>, and <em>Catharanthus roseus</em>, traditionally used to manage hypertension in Côte d’Ivoire.</p> <p><strong>Study Design:</strong> An experimental approach that combined phytochemical analyses, <em>In vitro</em> antioxidant assays, and <em>In vivo</em> cardiovascular investigations in rats was adopted.</p> <p><strong>Place and Duration of the Study:</strong> The study was conducted at the Laboratory of Bio-Organic Chemistry and Natural Substances (LCBOSN) and the Laboratory of Physiology, Pharmacology and Pharmacopoeia (L3P), both located at Nangui ABROGOUA University, from January to June 2026.</p> <p><strong>Methodology:</strong> Phytochemical screening and thin-layer chromatography (TLC) were performed. Phenolic compounds were quantified, and antioxidant activity was assessed using the DPPH assay, with vitamin C as a reference. Blood pressure and heart rate were monitored in rats.</p> <p><strong>Results:</strong> TLC analysis suggested the presence of flavonoids, coumarins, and other phenolic compounds. R2 exhibited antioxidant activity (CR<sub>50</sub>: 25–30 µg/mL), compared with 15–20 µg/mL for vitamin C. In rats, diastolic blood pressure decreased from day 6, while systolic and mean blood pressure decreased from day 12, accompanied by increased heart rate.</p> <p><strong>Conclusion:</strong> R2 exhibited antioxidant activity and blood pressure-lowering effects in rats, providing preliminary experimental support for its traditional use in hypertension management. Further studies are needed to establish its mechanisms of action and safety.</p> Kouamé Affoué Triphène Tapé Kouamé N’guessan Patrick Audrey Brédou Jean Brice Boua Boua Benson Békro Yves-Alain Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-18 2026-11-18 28 11 153 163 10.9734/jamps/2026/v28i11913 Antiviral Drug Development against RNA Viruses: Progress, Clinical Translation and Persistent Challenges https://journaljamps.com/index.php/JAMPS/article/view/903 <p>Antiviral drug development has produced transformative treatments for some RNA-virus infections while leaving major gaps in acute respiratory, haemorrhagic and enteric disease. The unevenness of progress cannot be explained by target availability alone. This critical narrative review examines how viral biology, pharmacological exposure, disease timing, trial design, resistance and health-system access jointly determine whether an antiviral candidate becomes a clinically useful intervention. Peer-reviewed mechanistic studies, randomised trials, methodological papers and authoritative institutional evidence published from 2000 to 13 August 2026 were critically synthesised, with earlier foundational findings considered where necessary. Durable combination treatment for human immunodeficiency virus and curative direct-acting treatment for hepatitis C show what sustained target validation and clinical development can achieve. Conversely, trials of influenza, coronavirus disease 2019, respiratory syncytial virus, dengue and emerging infections demonstrate the difficulty of translating reductions in viral replication into reliable effects on symptoms, hospitalisation, transmission or survival. Contrasting remdesivir outcomes across disease stages, context-dependent results for oral coronavirus antivirals, a promising but geographically limited paediatric respiratory syncytial virus trial, and dengue human-challenge studies illustrate why positive virological or early clinical findings require precise interpretation. Resistance is shaped by drug mechanism, treatment exposure, viral population dynamics and surveillance quality, rather than by a uniform property of all RNA viruses. Apparent broad-spectrum activity may also reflect assay artefacts or non-physiological experimental systems. Priorities include pharmacologically credible discovery platforms, earlier diagnosis and treatment, adaptive trials with prespecified patient-important endpoints, resistance-informed combinations, outbreak-ready trial infrastructure and affordability planned before licensing. The central conclusion is that antiviral innovation is most effective when molecular specificity, clinically relevant timing and equitable implementation are developed as a connected evidence pathway.</p> Nasir Ahmad Falaki Zephaniah Isaiah Abdullahi Usman Ndabata Raymond John Hafsat Abba Muhammad Hussaini Abubakar Ibrahim Muhammad Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-10-23 2026-10-23 28 11 1 19 10.9734/jamps/2026/v28i11903 Microneedle Patches for Vaccine Delivery: A Review of Formulation, Immunogenicity and Distribution Advantages https://journaljamps.com/index.php/JAMPS/article/view/905 <p>Microneedle patches are minimally invasive platforms designed to deliver vaccine antigens across the stratum corneum into the epidermal and dermal layers of the skin, where antigen-presenting cells can contribute to the induction of immune responses. This review examines major microneedle configurations, formulation considerations, immunogenicity, and potential logistical advantages relevant to vaccination. Solid, coated, dissolving, and hollow microneedles differ in their mechanisms of antigen incorporation and release. Among these systems, dissolving and coated microneedles have received particular attention for vaccine delivery. Formulation strategies using stabilising excipients such as trehalose and carboxymethylcellulose have been investigated to preserve antigen integrity during fabrication, drying, storage, and administration. Experimental studies with influenza, measles, and several other vaccine antigens have demonstrated humoral and cellular immune responses that can be comparable with conventional vaccination under specific study conditions. Early clinical studies of influenza and measles-rubella vaccines have also provided preliminary evidence of acceptable safety and immunogenicity. Microneedle patches may additionally offer practical advantages, including reduced sharps waste, single-dose presentation, avoidance of vaccine reconstitution, simplified administration, and the possibility of self-administration or administration by minimally trained personnel. However, important limitations remain regarding long-term antigen stability, dose uniformity, reproducible application, manufacturing scalability, sterilisation, and validation in larger and more diverse human populations. Continued clinical and manufacturing research is therefore required before widespread implementation.</p> Viraj Kamble Khushi Lawhale Riya Nakate Sakshi Nile Janhavi Pawar Nilofar Khan Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-10-29 2026-10-29 28 11 29 38 10.9734/jamps/2026/v28i11905 Inclusion of Native, Aboriginal and Tribal Populations in Genomic Medicine and Biorepositories: A Critical Narrative Review of Participation, Governance, Challenges and Guidelines for Equitable Indigenous Genomic Research https://journaljamps.com/index.php/JAMPS/article/view/909 <p>Genomic medicine depends on reference data, biobanks and association studies that remain dominated by participants of European ancestry, while Native, Aboriginal and Tribal peoples continue to be scarcely represented. This imbalance limits variant interpretation, pharmacogenomic prescribing and polygenic prediction for communities that already carry disproportionate burdens of disease. Calls for wider inclusion, however, collide with a history of extractive sampling, secondary use without consent and stigmatising publication, and with Indigenous assertions of collective rights over biological samples and data. This critical narrative review examines how Indigenous peoples have been included in, excluded from and have shaped genomic medicine and biorepository research, and appraises the governance instruments and guidelines that now regulate that participation. Literature published from 2000 onwards was identified through biomedical and multidisciplinary scholarly databases, citation tracking and the official websites of standard-setting bodies, and was appraised qualitatively for relevance, methodological transparency, community partnership and contribution. The synthesis indicates that under-representation is well documented and has measurable clinical consequences, including more variants of uncertain significance, reduced polygenic score accuracy and incomplete pharmacogenomic coverage. Empirical studies of attitudes show conditional rather than absent willingness to participate, with support depending on community governance, local benefit and control over secondary use. Governance has moved from individual informed consent towards collective oversight, tribal research codes, data sovereignty principles and Indigenous-led biobanks, yet these instruments are unevenly enforceable and largely confined to a few high-income settler states. Evidence from Africa, Latin America, South and Southeast Asia and the Arctic is thin, and outcome evaluations of governance models are almost absent. Important unresolved questions concern whether inclusion within national datasets serves Indigenous interests, how benefit sharing can be made concrete, and how ancestry-associated risk can be studied without biologising inequities that have social causes. Equitable Indigenous genomic research appears to require durable community authority over samples and data, investment in Indigenous scientific capacity and prospective evaluation of whether partnership models deliver health benefit.</p> Kai Jandial Raynald Samoa Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-10 2026-11-10 28 11 63 90 10.9734/jamps/2026/v28i11909 Key Points after Prostate Resection: A Narrative Review https://journaljamps.com/index.php/JAMPS/article/view/910 <p>Transurethral resection of the prostate (TURP) is an established treatment for benign prostatic obstruction, yet recovery after discharge requires symptom surveillance, individualised care and timely access to clinical assessment. This narrative review examines evidence relevant to urinary catheter management, haematuria, antithrombotic-related bleeding risk, infection prevention, continence rehabilitation, activity, nutrition, sexual well-being and continuity of nursing support. Randomised studies support earlier catheter removal in appropriately selected patients, whereas contemporary cohort studies identify clinically important variation in postoperative bleeding risk among patients receiving antiplatelet or anticoagulant treatment. Synthesised evidence supports perioperative antibiotic prophylaxis but does not justify unsupervised postoperative antimicrobial use. Structured nursing and discharge education may improve self-care ability or perceived discharge readiness; evidence for reductions in readmission and longer-term complications remains limited. Pelvic floor muscle training may benefit selected patients, but TURP-specific studies have not established a consistent long-term continence advantage. Recovery plans should address catheter status, safe medication use, individual activity advice, warning signs, urinary and sexual outcomes and planned review. The available literature supports practical, patient-centred discharge education coupled with risk-stratified follow-up rather than a uniform postoperative regimen.</p> Muhammad Abbas Muhammad Fahad Danish Ali Muhammad Faisal Zalan Akbar Abrar Khan Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-16 2026-11-16 28 11 91 99 10.9734/jamps/2026/v28i11910 Cardiovascular Disease Prevalence and Related Outcomes in Nigeria: A Critical Review of Evidence, Measurement Gaps and Care Outcomes https://journaljamps.com/index.php/JAMPS/article/view/912 <p><strong>Background:</strong> Nigeria is the most populous country in Africa and is passing through an epidemiological transition in which cardiovascular disease is assuming a larger share of adult morbidity, disability and premature death. Estimates of that burden nevertheless vary widely, and their reliability is rarely examined alongside the outcomes that matter to patients and health systems.</p> <p><strong>Purpose and Scope:</strong> This critical narrative review appraises evidence on the prevalence, incidence and related outcomes of adult cardiovascular disease in Nigeria, covering hypertension, stroke, heart failure and cardiomyopathies, rheumatic and other valvular disease, atrial fibrillation, coronary heart disease, the principal cardiometabolic risk factors, and mortality, economic and health-system outcomes.</p> <p><strong>Methods:</strong> Peer-reviewed literature and institutional reports were identified through structured searches of international and African bibliographic sources, supplemented by citation tracking. Studies were appraised qualitatively for sampling frame, case ascertainment, outcome completeness and analytical transparency, and the findings were synthesised thematically.</p> <p><strong>Principal Findings:</strong> Hypertension is the dominant and best-documented condition, affecting roughly one in three adults, with a narrowing urban–rural gradient and very low population-level control. It underlies most stroke, heart failure and sudden cardiac death in Nigerian series. Stroke carries high early case fatality, and heart failure affects relatively young adults with predominantly hypertensive aetiology. Peripartum cardiomyopathy shows a striking concentration in the North-West. Coronary heart disease appears to be rising, but its burden remains uncertain because diagnostic capacity is limited. Much of the evidence is hospital-based, regionally clustered and methodologically heterogeneous, and population-level mortality data remain scarce.</p> <p><strong>Unresolved Questions:</strong> True incidence trends, cause-specific mortality, long-term outcomes after stroke and heart failure, and the scalability of primary-care hypertension programmes remain poorly characterised.</p> <p><strong>Implications:</strong> Priorities include a standardised national cardiovascular surveillance platform linked to civil registration and verbal autopsy, population-based stroke and heart failure registries, financial protection for chronic cardiovascular care, and sustained investment in primary-care hypertension control.</p> <p><strong>Conclusion:</strong> The evidence supports treating hypertension control as the central lever for reducing cardiovascular harm in Nigeria, while emphasising that current burden estimates rest on fragile and uneven data.</p> Mary Ayodeji Olofin-Samuel Temitope Grace Ayo-Oluwaseyi Anuoluwa Deborah Odiru Deborah Adebimpe Awolumate Taiwo Folake Ojo Oluwabukola Ayo Gentry Waleola Bukola Ige Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0 2026-11-17 2026-11-17 28 11 124 152 10.9734/jamps/2026/v28i11912